SCHEMBL6661995

SCHEMBL6661995

CCC1CC(=O)N(Cc2ccc(NC(=O)c3cccs3)cc2)N=C1c1ccc(OC)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.53
MEN1 O00255 10/20 0.53
RAB9A P51151 7/20 0.53
NPC1 O15118 6/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
TP53 P04637 5/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 2/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 7/20 0.45
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
THRB P10828 1/20 0.45
BLM P54132 1/20 0.44
QRFPR Q96P65 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KLK7 P49862 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656699 0.94 KMT2A (0.51) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6654537 0.92 KMT2A (0.46) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6654929 0.92 KMT2A (0.46) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6654735 0.91 KMT2A (0.45) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6654593 0.90 KMT2A (0.44) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6657151 0.90 KMT2A (0.44) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6654399 0.90 KMT2A (0.44) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6660297 0.90 KMT2A (0.44) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6657846 0.90 KMT2A (0.44) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL6659487 0.89 PDE4A (0.50) KMT2AMEN1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B KMT2A 3056/4885MEN1 370/4885RAB9A 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.